Pharmaceuticals, Biotechnology and Life Sciences
MigVax is getting an investment of $12 million to accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market, as it pioneers the effort to develop Israel’s human vaccine against COVID-19.
Santhera Pharmaceuticals has been cleared in Israel for Raxone (idebenone) for visual impairment in adolescents and older, with Leber’s hereditary optic neuropathy (LHON).
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.